http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 08:30:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Cingulate+added+to+Russell+3000E+index/26724372.html <p>Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company based in Kansas City, Kansas, announced it has been added to the Russell 3000E Index.</p><p>The Russell 3000E Index tracks the performance of approximately 4,000 of the largest investable U.S. equities and serves as a benchmark for institutional investors. All Russell indexes are fully reconstituted each June, with semi-annual reconstitution set to begin in December 2026.</p><p>CEO Shane J. Schaffer said in a statement: "We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth."</p><p>Cingulate is developing pharmaceutical products using its Precision Timed Release http://www.streetinsider.com/Corporate+News/Cingulate+added+to+Russell+3000E+index/26724372.html Thu, 02 Jul 2026 08:30:56 -0400 CING CINGW http://www.streetinsider.com/Corporate+News/Cingulate+added+to+Russell+3000E+index/26724372.html <p>Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company based in Kansas City, Kansas, announced it has been added to the Russell 3000E Index.</p><p>The Russell 3000E Index tracks the performance of approximately 4,000 of the largest investable U.S. equities and serves as a benchmark for institutional investors. All Russell indexes are fully reconstituted each June, with semi-annual reconstitution set to begin in December 2026.</p><p>CEO Shane J. Schaffer said in a statement: "We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth."</p><p>Cingulate is developing pharmaceutical products using its Precision Timed Release http://www.streetinsider.com/Corporate+News/Cingulate+added+to+Russell+3000E+index/26724372.html Thu, 02 Jul 2026 08:30:56 -0400 CING CINGW http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Press+Releases/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html <p>KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has been added to the Russell 3000E® Index.</p> <p>&quot;Being added to the Russell 3000E® Index is a significant achievement that underscores Cingulate&apos;s continued evolution as a public company,&quot; said Cingulate CEO Shane J. Schaffer. &quot;We believe this inclusion will enhance our visibility with institutional investors, expand market awareness, and further position the company for long-term growth. As http://www.streetinsider.com/Globe+Newswire/Cingulate+Inc.+%28NASDAQ%3A+CING%29+Added+to+Russell+3000E%C2%AE/26724357.html Thu, 02 Jul 2026 08:30:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html <p>Cingulate Inc. (NASDAQ: CING) announced that the United States Patent and Trademark Office issued the company its first wholly owned U.S. patent covering its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), an ADHD treatment in development.</p><p>The patent, U.S. Patent No. 12,653,791, was issued June 16, 2026, and provides protection through December 2042. Titled "Trimodal, Precision-Timed Pulsatile Release Tablet," it covers composition-of-matter, formulation, structural, and method-of-treatment claims related to CTx-1301's tablet technology, which is designed to release medication in three distinct phases from a single daily dose.</p><p>Cingulate CEO Shane J. Schaffer said in a statement: "This patent represents another important milestone in http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html Tue, 16 Jun 2026 08:02:00 -0400 CING CINGW http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html <p>Cingulate Inc. (NASDAQ: CING) announced that the United States Patent and Trademark Office issued the company its first wholly owned U.S. patent covering its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), an ADHD treatment in development.</p><p>The patent, U.S. Patent No. 12,653,791, was issued June 16, 2026, and provides protection through December 2042. Titled "Trimodal, Precision-Timed Pulsatile Release Tablet," it covers composition-of-matter, formulation, structural, and method-of-treatment claims related to CTx-1301's tablet technology, which is designed to release medication in three distinct phases from a single daily dose.</p><p>Cingulate CEO Shane J. Schaffer said in a statement: "This patent represents another important milestone in http://www.streetinsider.com/Corporate+News/Cingulate+receives+first+U.S.+patent+for+ADHD+drug+candidate+CTx-1301/26650757.html Tue, 16 Jun 2026 08:02:00 -0400 CING CINGW http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795 http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html <p>KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</p> <p>The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, http://www.streetinsider.com/Press+Releases/Cingulate+Issued+First+U.S.+Patent+for+Lead+ADHD+Asset+CTx-1301/26650745.html Tue, 16 Jun 2026 08:00:00 -0400 A.14320728 A.23650007 CING CINGW O.20250741 O.41161166 O.52480795